Trial of BDC-1001 +/- Pertuzumab in Subjects With HER2-Positive Metastatic Breast Cancer

Stopped early · Phase 2

Conditions studied: Metastatic Breast Cancer, HER2-positive Breast Cancer

In brief

This is an open-label, Phase 2 study to evaluate preliminary anti-tumor activity, safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of BDC-1001 administered as a single agent and in combination with pertuzumab in subjects with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC) previously treated with trastuzumab deruxtecan (Enhertu®).

Key facts

Study ID

NCT05954143

Run by

Bolt Biotherapeutics, Inc.

People needed

11

Starts

2023-11-30

Expected to finish

2024-09-25

Last updated by the study team

2025-11-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope — Irvine, California, United States
• Memorial Sloan Kettering Cancer Center — New York, New York, United States
• Virginia Cancer Specialists — Arlington, Virginia, United States
• Hospital Universitario 12 de Octubre — Madrid, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.